RxDoctor Payments Data

Andrea Martinez Villalobos

Physician Assistant · Central Islip, NYNPI 1003280041

Payments from drug & device makers

$702in general payments, 2019–2025

Across 22 payments — averaging $31.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Haemonetics Corporation$148
  • AbbVie$142
  • Teva Pharmaceuticals USA, Inc.$74
  • Amarin Pharma, Inc.$61
  • Otsuka America Pharmaceutical, Inc.$59
  • Lundbeck LLC$38
  • plus $181 from 7 others

What the payments were for

  • Food & beverage$702100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$702 in reported general payments places this provider in the 70th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$474
Medicare patients
33
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate45$32,838
MounjaroTirzepatide27$27,746
VascepaIcosapent Ethyl58$23,203
JardianceEmpagliflozin27$20,639
OzempicSemaglutide13$12,799
Icosapent Ethyl32$7,289
Levothyroxine Sodium220$1,738
Midodrine Hcl12$1,724
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,659
Atorvastatin Calcium223$1,425
Alendronate Sodium77$1,421
Albuterol Sulfate HfaAlbuterol Sulfate26$1,366
Fluticasone Propionate68$1,233
Simvastatin172$1,131
Omeprazole134$1,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$19$32,83845 claims
Lilly USA, LLCMounjaro$23$27,74627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Central Islip

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →